Patents by Inventor Darrell Carney

Darrell Carney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230165943
    Abstract: Certain embodiments are directed to using TP508 as a drug that can restore prevent alveolar damage, reducing pulmonary edema and prevent respiratory failure and mortality-associated progression of COVID-19.
    Type: Application
    Filed: April 7, 2021
    Publication date: June 1, 2023
    Inventors: LAURIE E. SOWER, DARRELL CARNEY
  • Patent number: 10220078
    Abstract: Provided herein are methods for using a thrombin peptide derivative to treat a medulloblastoma. In one embodiment, the method includes administering to a subject having a medulloblastoma an effective amount of a thrombin peptide derivative, and exposing cells of the medulloblastoma of the subject to a cancer treatment after administering the thrombin peptide derivative to the subject. An example of a cancer treatment is radiation therapy. In one embodiment, viability of cells of the medulloblastoma is decreased compared to viability of cells of the medulloblastoma before the administering and the exposing. The cells of the medulloblastoma having decreased viability can be cancer stem cells. In one embodiment, shrinkage of the medulloblastoma in the subject is increased compared to shrinkage of the medulloblastoma before the administering and the exposing.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: March 5, 2019
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Darrell Carney, Carla Kantara, Stephanie Moya
  • Publication number: 20150359855
    Abstract: Provided herein are methods for using a thrombin peptide derivative to treat a medulloblastoma. In one embodiment, the method includes administering to a subject having a medulloblastoma an effective amount of a thrombin peptide derivative, and exposing cells of the medulloblastoma of the subject to a cancer treatment after administering the thrombin peptide derivative to the subject. An example of a cancer treatment is radiation therapy. In one embodiment, viability of cells of the medulloblastoma is decreased compared to viability of cells of the medulloblastoma before the administering and the exposing. The cells of the medulloblastoma having decreased viability can be cancer stem cells. In one embodiment, shrinkage of the medulloblastoma in the subject is increased compared to shrinkage of the medulloblastoma before the administering and the exposing.
    Type: Application
    Filed: June 11, 2015
    Publication date: December 17, 2015
    Inventors: Darrell Carney, Carla Kantara, Stephanie Moya
  • Publication number: 20060241049
    Abstract: Disclosed is a method of promoting healing of a chronic dermal skin ulcer, such as a diabetic ulcer, on a subject. The method comprises the step of contacting the chronic dermal skin ulcer with an effective amount of an agonist of the non-proteolytically activated thrombin receptor.
    Type: Application
    Filed: April 4, 2006
    Publication date: October 26, 2006
    Inventor: Darrell Carney
  • Publication number: 20060134167
    Abstract: The present invention relates to a method for promoting cardiac tissue repair comprising administering to the cardiac tissue a therapeutically effective amount of an angiogenic thrombin derivative peptide and/or inhibiting or reducing vascular occlusion or restenosis. The invention also relates to methods of stimulating revascularization. In yet another embodiment, the invention relates to the use of thrombin derivative peptides in the manufacture of a medicament for the methods described herein.
    Type: Application
    Filed: December 2, 2005
    Publication date: June 22, 2006
    Inventor: Darrell Carney
  • Publication number: 20050227923
    Abstract: Disclosed is a method of stimulating bone growth at a site in a subject in need of osteoinduction. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site.
    Type: Application
    Filed: January 18, 2005
    Publication date: October 13, 2005
    Applicant: The Board of Regents, The University of Texas System
    Inventors: Darrell Carney, Roger Crowther, David Simmons, Jinping Yang, William Redin
  • Publication number: 20050203017
    Abstract: Disclosed are pharmaceutical compositions comprising a thrombin peptide derivatives and a chelating agent and/or a pharmaceutically acceptable thiol-containing compound. The pharmaceutical compositions optionally further comprise an antioxidant. Also, disclosed are methods for activating the non-proteolytically activated thrombin receptor in a subject in need of such treatment. The methods comprise the step of administering an effective amount of a thrombin peptide derivative in the pharmaceutical composition described above.
    Type: Application
    Filed: December 30, 2004
    Publication date: September 15, 2005
    Applicant: The Board of Regents, The University of Texas System
    Inventors: David Hobson, Roger Crowther, Darrell Carney, Andrew Tang
  • Publication number: 20050181996
    Abstract: Disclosed is a method of stimulating cartilage growth, repair or regeneration at a site in a subject in need of such growth, repair or regeneration. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site. Also disclosed is a method of stimulating the proliferation and expansion of chrondrocytes in vitro. The method comprises culturing chrondrocytes in the presence of a stimulating amount of an NPAR agonist.
    Type: Application
    Filed: November 29, 2004
    Publication date: August 18, 2005
    Applicant: The Board of Regents, The University of Texas System
    Inventors: Darrell Carney, Roger Crowther, Janet Stiernberg, John Bergmann
  • Publication number: 20050158301
    Abstract: Disclosed are thrombin peptide derivatives comprising a polypeptide having the amino acid sequence SEQ ID NO. 2: Arg-Gly-Asp-Ala-Xaa-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val, or a C-terminal truncated fragment of the polypeptide having at least six amino acids. Xaa is alanine, glycine, serine, or an S-protected cysteine. Zero, one, two, or three amino acids in the polypeptide or polypeptide fragment differ from the corresponding position of SEQ ID NO. 2. Also disclosed are methods of treating a subject in need of treatment with a thrombin receptor agonist. The methods comprise the step of administering an effective amount of the thrombin peptide derivative described above.
    Type: Application
    Filed: December 30, 2004
    Publication date: July 21, 2005
    Applicant: The Board of Regents, The University of Texas System
    Inventor: Darrell Carney
  • Publication number: 20050153893
    Abstract: Disclosed are thrombin peptide derivative dimers comprising two polypeptides having the amino acid sequence SEQ ID NO. 2: Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val, or a C-terminal truncated fragment of the polypeptide having at least six amino acids. Zero, one, two, or three amino acids in the polypeptide or polypeptide fragment differ from the corresponding position of SEQ ID NO. 2. Also disclosed are methods of treating a subject in need of treatment with a thrombin receptor agonist. The methods comprise the step of administering an effective amount of the thrombin peptide derivative described above.
    Type: Application
    Filed: December 30, 2004
    Publication date: July 14, 2005
    Applicant: The Board of Regents, The University of Texas System
    Inventor: Darrell Carney
  • Publication number: 20050153884
    Abstract: The present invention relates to a method for promoting cardiac tissue repair comprising administering to the cardiac tissue a therapeutically effective amount of an angiogenic thrombin derivative peptide and/or inhibiting or reducing vascular occlusion or restenosis. The invention also relates to methods of stimulating revascularization. In yet another embodiment, the invention relates to the use of thrombin derivative peptides in the manufacture of a medicament for the methods described herein.
    Type: Application
    Filed: September 30, 2004
    Publication date: July 14, 2005
    Applicant: The Board of Regents, The University of Texas System
    Inventor: Darrell Carney
  • Publication number: 20050019331
    Abstract: These compositions are new synthetic peptides and antibodies which are potent chemotactic agents for human neutrophils, and methods for their use. The specificity of these peptides is amino acid sequence specific for binding to a heretofore unidentified receptor on the surface of neutrophils. Neutrophil response to this peptide is specific, since monocytes and fibroblasts do not show any expression of this receptor. Antibodies against these peptides block the chemotactic response. Such antibodies are useful to modulate neutrophil recruitment to a wound site for enhancing or inhibiting inflammation and early effects of wound healing.
    Type: Application
    Filed: November 20, 2003
    Publication date: January 27, 2005
    Applicant: Chrysalis Biotechnology
    Inventors: Darrell Carney, Shyam Ramakrishnan